5′-Triphosphate-siRNA against survivin gene induces interferon production and inhibits proliferation of lung cancer cells in vitro

Journal of Immunotherapy

Volumn 36, Issue 5, 2013, Pages 294-304

  Wang, Kai ^a,b   Chen, Xiaojuan ^b   Yan, Fei ^b   Xing, Yaling ^b   Yang, Xingxing ^b   Tu, Jian ^c   Chen, Zhongbin ^a,b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^c MACQUARIE UNIVERSITY   (Australia)

Author keywords

50 triphosphated sirna; Ifn a b; Lung cancer cell; Rnai; Survivin

Indexed keywords

5' TRIPHOSPHATE SMALL INTERFERING RNA; INTERFERON; SMALL INTERFERING RNA; SURVIVIN; UNCLASSIFIED DRUG; BETA INTERFERON; BIRC5 PROTEIN, HUMAN; DDX58 PROTEIN, HUMAN; DEAD BOX PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; POLYPHOSPHATE; RADIOSENSITIZING AGENT; TRIPHOSPHORIC ACID;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERFERON PRODUCTION; LUNG CANCER; PRIORITY JOURNAL; RNA INTERFERENCE; CARCINOMA; CELL GROWTH; CHEMISTRY; CHEMORADIOTHERAPY; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; INNATE IMMUNITY; LUNG NEOPLASMS; METABOLISM; RADIATION; TRANSGENE; CELL STRAIN HEK293; LUNG TUMOR;

APOPTOSIS; CARCINOMA; CELL GROWTH PROCESSES; CHEMORADIOTHERAPY; DEAD-BOX RNA HELICASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; IMMUNITY, INNATE; INHIBITOR OF APOPTOSIS PROTEINS; INTERFERON-BETA; LUNG NEOPLASMS; POLYPHOSPHATES; RADIATION; RADIATION-SENSITIZING AGENTS; RNA, SMALL INTERFERING; TRANSGENES;

EID: 84880246412     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318294183b     Document Type: Article

References (41)

1. Wheatley SP, McNeish IA. Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol. 2005;247:35-88.
2. Mó nzo M, Rosell R, Felip E, et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol. 1999;17: 2100-2104.
3. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-921.
4. Rödel F, Hoffmann J, Distel L, et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res. 2005;65:4881-4887.
5. Chakravarti A, Zhai GG, Zhang M, et al. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene. 2004;23: 7494-7506.
6. Cao C, Mu Y, Hallahan DE, et al. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene. 2004;23:7047-7052.
7. Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: the cell-signalling perspective. Drug Discov Today. 2011;16:485-494.
8. Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev. 2009;35:553-562.
9. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46-54.
10. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8:61-70.
11. Chang CC, Heller JD, Kuo J, et al. Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci USA. 2004;101:13239-13244.
12. Howard KA, Rahbek UL, Liu X, et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther. 2006;14:476-484.
13. Caplen NJ, Parrish S, Imani F, et al. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acid Sci USA. 2001;98:9742-9747.
14. Pai SI, Lin YY, Macaes B, et al. Prospects of RNA interference therapy for cancer. Gene Ther. 2006;13:464-477.
15. Grimm D, Kay MA. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest. 2007;117:3633-3641.
16. Uchida H, Tanaka T, Sasaki K, et al. Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther. 2004;10:162-171.
17. Li QX, Zhao J, Liu JY, et al. Survivin stable knockdown by sirna inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther. 2006;5:860-866.
18. Wenying Z, Zhaoning J, Zhimin Y, et al. Survivin siRNA inhibits gastric cancer in nude mice. Cell Biochem Biophys. 2012;62:337-341.
19. Hendruschk S, Wiedemuth R, Aigner A, et al. RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neurol Oncol. 2011;13:1074-1089.
20. Kami K, Doi R, Koizumi M, et al. Downregulation of survivin by siRNA diminished radioresistance of pancreatic cancer cells. Surgery. 2005;138:299-305.
21. Schmidt A, Schwerd T, Hamm W, et al. 50-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proc Natl Acad Sci USA. 2009;106: 12067-12072.
22. Cui S, Eisenacher K, Kirchhofer A, et al. The C-terminal regulator domain is the RNA 50-triphosphate sensor of RIG-I. Mol Cell. 2008;29:169-179.
23. Jiang F, Ramanathan A, Miller MT, et al. Structural basis of RNA recognition and activation by innate immune receptor RIG-I. Nature. 2011;479:423-427.
24. Bowzard JB, Davis WG, Jeisy-Scott V, et al. PAMPer and tRIGer: ligand-induced activation of RIG-I. Trends Biochem Sci. 2011;36:314-319.
25. Hornung V, Ellegast J, Kim S, et al. 50-Triphosphate RNA is the ligand for RIG-I. Science. 2006;314:994-997.
26. Pichlmair A, Schulz O, Tan CP, et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 50-phosphate. Science. 2006;314:997-1001.
27. Paduano F, Villa R, Pennati M, et al. Silencing of survivin gene by small interfering RNAs produces super-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther. 2006;5:179-186.
28. Poeck H, Besch R, Maihoefer C, et al. 50-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med. 2008;14:1256-1263.
29. Sumper R Jr, Loo YM, Foy E, et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C Virus RNA replication through a cellular RNA helicase, RIG-I. J Virol. 2005;79:2689-2699.
30. Han Q, Zhang C, Zhang J, et al. Reversal of hepatitis B virusinduced immune tolerance by an immunostimulatory 3p-HBxsiRNAs in a retinoic acid inducible gene I-dependent manner. Hepatology. 2011;54:1179-1189.
31. Siegel R, Desantis C, Virgo K, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2012;62:220-241.
32. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
33. Zhang LQ, Wang J, Jiang F, et al. Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PLoS One. 2012;7:e34100.
34. Tanabe H, Yagihashi A, Tsuji N, et al. Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer. Lung Cancer. 2004;46:299-304.
35. Chen P, Li J, Ge LP, et al. Prognostic value of survivin, X-linked inhibitor of apop-tosis protein and second mitochondria-derived activator of caspase expression in advanced nonsmall-cell lung cancer patients. Respirology. 2010;15:501-509.
36. Kuo PC, Liu HF, Chao JI. Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells. J Biol Chem. 2004;279:55875-55885.
37. Olie RA, Simoes-Wust AP, Baumann B, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 2000;60:2805-2809.
38. Lu B, Mu Y, Cao C, et al. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res. 2004;64: 2840-2845.
39. Zitzmann K, Brand S, De Toni EN, et al. SOCS1 silencing enhances autitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res. 2007;67: 5025-5032.
40. Fueres MB, Woo SR, Burnett B, et al. Type I interferon response and innate immune sensing of cancer. Trends Immunol. 2013;34:67-73.
41. Ebert G, Poeck H, Lucifora J, et al. 50 Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice. Gastroenterology. 2011;141:696-706, 706.e1-3.